Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Organon & Co. Common Stock — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.6 (market cap $79.86B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 22.1× Organon & Co. Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Organon & Co. Common Stock for 0 Days on average.
| MDLZ | OGN | |
|---|---|---|
Market Cap | $79.86B | $3.61B |
Volume | 7,299,804 | 1,808,049 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $13.81 |
52-Week Low | $51.51 | $5.70 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $100.20B | $11.03B |
Dividend Yield | 3.32% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $61.50, down 0.47% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54 billion in 2025, though net income margin declined to 6.36% from 12.65% in 2024. Analyst consensus remains strongly bullish with a $70.29 price target, representing 14% upside potential.
MDLZ offers attractive valuation with a P/E of 22.53 and consistent dividend growth, recently raising its quarterly payout to $0.52. Key risks include cocoa cost pressures and margin compression, but the company's global brand strength and emerging market momentum provide stability. The stock presents a compelling opportunity for long-term investors seeking defensive exposure with dividend income.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
